158 related articles for article (PubMed ID: 28239601)
1. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.
Rumman A; Candia R; Sam JJ; Croitoru K; Silverberg MS; Steinhart AH; Nguyen GC
Can J Gastroenterol Hepatol; 2017; 2017():7365937. PubMed ID: 28239601
[No Abstract] [Full Text] [Related]
2. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States.
Lin KK; Sewell JL
Am J Gastroenterol; 2013 Dec; 108(12):1824-30. PubMed ID: 24300857
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study.
Desai RJ; Gagne JJ; Lii J; Liu J; Friedman S; Kim SC
CMAJ; 2017 Nov; 189(47):E1438-E1447. PubMed ID: 29180383
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.
Targownik LE; Benchimol EI; Witt J; Bernstein CN; Singh H; Lix L; Tennakoon A; Zubieta AA; Coward S; Jones J; Kuenzig E; Murthy SK; Nguyen GC; Peña-Sánchez JN; Kaplan G
Inflamm Bowel Dis; 2019 Sep; 25(10):1718-1728. PubMed ID: 31211836
[TBL] [Abstract][Full Text] [Related]
5. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
[TBL] [Abstract][Full Text] [Related]
6. Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing.
Connell WR; Samyue T; Gibson PR; Lachal S; Moore GT; Macrae FA; Van Langenberg DR
Intern Med J; 2015 Nov; 45(11):1161-6. PubMed ID: 26178007
[TBL] [Abstract][Full Text] [Related]
7. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
[TBL] [Abstract][Full Text] [Related]
8. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease.
Benchimol EI; Mack DR; Nguyen GC; Snapper SB; Li W; Mojaverian N; Quach P; Muise AM
Gastroenterology; 2014 Oct; 147(4):803-813.e7; quiz e14-5. PubMed ID: 24951840
[TBL] [Abstract][Full Text] [Related]
9. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
10. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
12. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
13. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
[TBL] [Abstract][Full Text] [Related]
14. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015).
Kim JW; Lee CK; Lee JK; Jeong SJ; Oh SJ; Moon JR; Kim HS; Kim HJ
Scand J Gastroenterol; 2019 Apr; 54(4):419-426. PubMed ID: 30905222
[No Abstract] [Full Text] [Related]
15. Postoperative health-care utilization in Crohn's disease: the impact of specialist care.
Nguyen GC; Saibil F; Steinhart AH; Li Q; Tinmouth JM
Am J Gastroenterol; 2012 Oct; 107(10):1522-9. PubMed ID: 22850430
[TBL] [Abstract][Full Text] [Related]
16. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
17. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
19. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
[TBL] [Abstract][Full Text] [Related]
20. Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study.
Nguyen GC; Bouchard S; Diong C;
J Crohns Colitis; 2019 Mar; 13(3):330-336. PubMed ID: 30312376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]